

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxytoclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

SECTION 1. IDENTIFICATION

Product name : Oxfendazole / Oxytoclozanide Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary medicine
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

Reproductive toxicity : Category 1B

Specific target organ toxicity : Category 2 (Central nervous system)
- single exposure (Oral)

Specific target organ toxicity : Category 2 (Liver, Testis, Brain)
- repeated exposure

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.
H360FD May damage fertility. May damage the unborn child.
H371 May cause damage to organs (Central nervous system) if swallowed.
H373 May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxyclozanide Formulation

Version 5.0 Revision Date: 06/20/2025 SDS Number: 7942487-00009 Date of last issue: 04/14/2025
Date of first issue: 03/19/2021

Precautionary Statements :

Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:
P308 + P311 IF exposed or concerned: Call a doctor.
P308 + P313 IF exposed or concerned: Get medical attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS No./Unique ID	Concentration (% w/w)	Trade secret
Oxyclozanide	2277-92-1*	>= 30 - <= 60	TSC
oxfendazole	53716-50-0*	>= 10 - <= 30	TSC
Starch, oxidized	65996-62-5*	>= 10 - <= 30	TSC
Magnesium stearate	557-04-0*	>= 0.5 - <= 1.5	TSC

* Indicates that the identifier is a CAS No.

TSC- the actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

In case of eye contact	:	Wash clothing before reuse. Thoroughly clean shoes before reuse. If in eyes, rinse well with water.
If swallowed	:	Get medical attention if irritation develops and persists. If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed	:	Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. May damage fertility. May damage the unborn child. May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Chlorine compounds Nitrogen oxides (NO _x) Metal oxides Oxides of phosphorus
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

- | | | |
|---|---|--|
| Personal precautions, protective equipment and emergency procedures | : | Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
| Environmental precautions | : | Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained. |
| Methods and materials for containment and cleaning up | : | Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements. |

SECTION 7. HANDLING AND STORAGE

- | | | |
|-----------------------------|---|--|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment. |
| Conditions for safe storage | : | Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations. |

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxytoclozanide Formulation

Version 5.0 Revision Date: 06/20/2025 SDS Number: 7942487-00009 Date of last issue: 04/14/2025
Date of first issue: 03/19/2021

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

inert or nuisance dust 50 Million particles per cubic foot
Value type (Form of exposure): TWA (total dust)
Basis: OSHA Z-3

15 mg/m³
Value type (Form of exposure): TWA (total dust)
Basis: OSHA Z-3

5 mg/m³
Value type (Form of exposure): TWA (respirable fraction)
Basis: OSHA Z-3

15 Million particles per cubic foot
Value type (Form of exposure): TWA (respirable fraction)
Basis: OSHA Z-3

Dust, nuisance dust and particulates 10 mg/m³
Value type (Form of exposure): PEL (Total dust)
Basis: CAL PEL

5 mg/m³
Value type (Form of exposure): PEL (respirable dust fraction)
Basis: CAL PEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Oxytoclozanide	2277-92-1	TWA	0.4 mg/m ³ (OEB 2)	Internal
oxfendazole	53716-50-0	TWA	40 µg/m ³ (OEB 3)	Internal
		Wipe limit	400 µg/100 cm ²	Internal
Starch, oxidized	65996-62-5	TWA (Inhalable dust)	0.5 mg/m ³	ACGIH
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxcyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

Color	:	white to off-white, light cream, cream
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	0.88 g/cm ³
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxylozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
---------------------	---	--

Components:

Oxylozanide:

Acute oral toxicity	:	LD50 (Rat): 3,519 mg/kg Target Organs: Central nervous system
Acute toxicity (other routes of administration)	:	LDLo (sheep): 10 mg/kg Application Route: Intravenous

oxfendazole:

Acute oral toxicity	:	LD50 (Rat): > 6,000 mg/kg LD50 (Dog): 1,600 mg/kg LD50 (sheep): 250 mg/kg
---------------------	---	---

Magnesium stearate:

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 423 Assessment: The substance or mixture has no acute oral tox-
---------------------	---	---

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

	icity
	Remarks: Based on data from similar materials
Acute dermal toxicity	: LD50 (Rabbit): > 2,000 mg/kg
	Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

Oxclozanide:

Remarks	: Not classified due to lack of data.
---------	---------------------------------------

oxfendazole:

Species	: Rabbit
Result	: No skin irritation

Magnesium stearate:

Species	: Rabbit
Result	: No skin irritation
Remarks	: Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Oxclozanide:

Remarks	: Not classified due to lack of data.
---------	---------------------------------------

oxfendazole:

Species	: Rabbit
Result	: No eye irritation

Magnesium stearate:

Species	: Rabbit
Result	: No eye irritation
Remarks	: Based on data from similar materials

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxyκλοzanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

Components:

Oxyκλοzanide:

Routes of exposure	: Dermal
Remarks	: Not classified due to lack of data.

Magnesium stearate:

Test Type	: Maximization Test
Routes of exposure	: Skin contact
Species	: Guinea pig
Method	: OECD Test Guideline 406
Result	: negative
Remarks	: Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

Oxyκλοzanide:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive Test Type: Mouse Lymphoma Result: positive
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

oxfendazole:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Mouse Application Route: Oral

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxcyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

Result: positive

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

Oxcyclozanide:

Remarks : Not classified due to lack of data.

oxfendazole:

Species : Rat
Application Route : Oral
Exposure time : 1 Years
Symptoms : No adverse effects.
Target Organs : Liver

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Symptoms : No adverse effects.
Target Organs : Liver

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:

Oxcyclozanide:

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxytoclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat, male and female Application Route: Oral General Toxicity Parent: NOAEL: 25 - 35 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofetal and postnatal development. Result: No effects on fertility. Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity Parent: LOAEL: 75 - 100 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofetal and postnatal development. Result: No effects on fertility. Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight Result: No fetotoxicity., No teratogenic effects. Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity Parent: LOAEL: 80 - 160 mg/kg body weight Result: No fetotoxicity., No teratogenic effects., No effects on fertility.
Effects on fetal development	: Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 200 mg/kg body weight Result: No fetotoxicity., No teratogenic effects. Test Type: Development Species: Rat Application Route: Oral General Toxicity Maternal: LOAEL: 100 mg/kg body weight Result: No fetotoxicity., No teratogenic effects. Test Type: Development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 32 mg/kg body weight Result: Fetotoxicity., Skeletal malformations.
Reproductive toxicity - Assessment	: Suspected of damaging the unborn child.

oxfendazole:

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat, male
----------------------	---

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

		Application Route: Oral Fertility: NOAEL: 17 mg/kg body weight Target Organs: Testes Result: Effects on fertility.
		Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Fertility: NOAEL: 0.9 mg/kg body weight Target Organs: Liver Result: No effects on fertility.
		Test Type: Fertility Species: Mouse Application Route: Oral Duration of Single Treatment: 1 Months Fertility: NOAEL: 750 mg/kg body weight Target Organs: Testes Result: Effects on fertility.
Effects on fetal development	:	Test Type: Embryo-fetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Fetal effects.
		Test Type: Embryo-fetal development Species: Rat Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Embryo-fetal toxicity.
		Test Type: Embryo-fetal development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 108 mg/kg body weight Result: positive, Embryo-fetal toxicity., Fetal abnormalities.
		Test Type: Embryo-fetal development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 0.625 mg/kg body weight
Reproductive toxicity - Assessment	:	Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.
Magnesium stearate:		
Effects on fertility	:	Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 422

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

	Result: negative
	Remarks: Based on data from similar materials
Effects on fetal development	: Test Type: Embryo-fetal development
	Species: Rat
	Application Route: Ingestion
	Result: negative
	Remarks: Based on data from similar materials

STOT-single exposure

May cause damage to organs (Central nervous system) if swallowed.

Components:

Oxytetracycline:

Routes of exposure	: Oral
Target Organs	: Central nervous system
Assessment	: May cause damage to organs.

STOT-repeated exposure

May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.

Components:

Oxytetracycline:

Target Organs	: Brain, Liver
Assessment	: May cause damage to organs through prolonged or repeated exposure.

oxfendazole:

Routes of exposure	: Oral
Target Organs	: Liver, Testis
Assessment	: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Oxytetracycline:

Species	: Rat
NOAEL	: 9 mg/kg
LOAEL	: 44.5 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Brain, Liver, spleen, Adrenal gland
Symptoms	: Liver effects

Species	: Dog
NOAEL	: 5 mg/kg
LOAEL	: 25 mg/kg
Application Route	: Oral

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxcyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

Exposure time	: 3 Months
Target Organs	: Brain, Liver
Symptoms	: blood effects, alteration in liver enzymes

oxfendazole:

Species	: Rat
NOAEL	: 11 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Target Organs	: Blood, Liver, Testis

Species	: Rat
NOAEL	: 3.8 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Liver, Testis

Species	: Mouse
NOAEL	: 750 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Target Organs	: Liver

Species	: Mouse
NOAEL	: 37.5 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Liver

Species	: Dog
NOAEL	: 6 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Remarks	: No significant adverse effects were reported

Species	: Dog
NOAEL	: 11 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Target Organs	: Lymph nodes, thymus gland

Species	: Dog
NOAEL	: 13.5 mg/kg
Application Route	: Oral
Exposure time	: 12 Months
Target Organs	: Liver

Starch, oxidized:

Species	: Rat
NOAEL	: 22,500 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxcyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

Magnesium stearate:

Species	: Rat
NOAEL	: > 100 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Remarks	: Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Components:

Oxcyclozanide:

|| Not applicable

Experience with human exposure

Components:

Oxcyclozanide:

Ingestion	: Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression
-----------	--

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Oxcyclozanide:

Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 0.69 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
---	--

oxfendazole:

Toxicity to fish	: LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2.7 mg/l Exposure time: 96 h LC50 (Oncorhynchus mykiss (rainbow trout)): > 2.5 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 0.059 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): > 4

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxytetracycline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

	mg/l
	Exposure time: 72 h
	Method: OECD Test Guideline 201
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 0.023 mg/l
	Exposure time: 21 d
	Method: OECD Test Guideline 211

Magnesium stearate:

Toxicity to fish	: LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
	Exposure time: 48 h
	Method: DIN 38412
	Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	: EL50 (Daphnia magna (Water flea)): > 1 mg/l
	Exposure time: 47 h
	Test substance: Water Accommodated Fraction
	Method: Directive 67/548/EEC, Annex V, C.2.
	Remarks: Based on data from similar materials
	No toxicity at the limit of solubility.
Toxicity to algae/aquatic plants	: EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
	Exposure time: 72 h
	Test substance: Water Accommodated Fraction
	Method: OECD Test Guideline 201
	Remarks: Based on data from similar materials
	No toxicity at the limit of solubility.
	NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
	Exposure time: 72 h
	Test substance: Water Accommodated Fraction
	Method: OECD Test Guideline 201
	Remarks: Based on data from similar materials
Toxicity to microorganisms	: EC10 (Pseudomonas putida): > 100 mg/l
	Exposure time: 16 h
	Test substance: Water Accommodated Fraction
	Remarks: Based on data from similar materials

Persistence and degradability

Components:

Oxytetracycline:

Stability in water	: Hydrolysis: 50 % (156 d)
	Method: OECD Test Guideline 111

oxfendazole:

Stability in water	: Hydrolysis: < 5 % (4 d)
--------------------	---------------------------

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

Magnesium stearate:

Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Oxclozanide:

Partition coefficient: n-octanol/water : log Pow: 3.99
pH: 7
Method: OECD Test Guideline 107

oxfendazole:

Partition coefficient: n-octanol/water : log Pow: 1.95

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

Components:

Oxclozanide:

Distribution among environmental compartments : log Koc: 4.83
Method: OECD Test Guideline 106

oxfendazole:

Distribution among environmental compartments : log Koc: 3.2

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

N.O.S.
(oxfendazole, oxyclozanide)

Class	:	9
Packing group	:	III
Labels	:	9
Environmentally hazardous	:	yes

IATA-DGR

UN/ID No.	:	UN 3077
Proper shipping name	:	Environmentally hazardous substance, solid, n.o.s. (oxfendazole, Oxyclozanide)
Class	:	9
Packing group	:	III
Labels	:	Miscellaneous
Packing instruction (cargo aircraft)	:	956
Packing instruction (passenger aircraft)	:	956
Environmentally hazardous	:	yes

IMDG-Code

UN number	:	UN 3077
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (oxfendazole, Oxyclozanide)
Class	:	9
Packing group	:	III
Labels	:	9
EmS Code	:	F-A, S-F
Marine pollutant	:	yes

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Domestic regulation

49 CFR

UN/ID/NA number	:	UN 3077
Proper shipping name	:	Environmentally hazardous substance, solid, n.o.s. (oxfendazole, Oxyclozanide)
Class	:	9
Packing group	:	III
Labels	:	CLASS 9
ERG Code	:	171
Marine pollutant	:	yes(oxfendazole, Oxyclozanide)
Remarks	:	Above applies only to containers over 119 gallons or 450 liters. Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxcyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust
Reproductive toxicity
Specific target organ toxicity (single or repeated exposure)

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Oxcyclozanide	2277-92-1
oxfendazole	53716-50-0
Starch, oxidized	65996-62-5
Polyvinyl pyrrolidone	9003-39-8

California List of Hazardous Substances

Polyvinyl pyrrolidone	9003-39-8
-----------------------	-----------

California Permissible Exposure Limits for Chemical Contaminants

Starch, oxidized	65996-62-5
Magnesium stearate	557-04-0

The ingredients of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

SECTION 16. OTHER INFORMATION

Further information

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxcyclozanide Formulation


Version
5.0

Revision Date:
06/20/2025

SDS Number:
7942487-00009

Date of last issue: 04/14/2025
Date of first issue: 03/19/2021

NFPA 704:



HMIS® IV:

HEALTH	*	3
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
CAL PEL	:	California permissible exposure limits for chemical contaminants (Title 8, Article 107)
OSHA Z-3	:	USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts
ACGIH / TWA	:	8-hour, time-weighted average
CAL PEL / PEL	:	Permissible exposure limit
OSHA Z-3 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Oxfendazole / Oxclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/20/2025	7942487-00009	Date of first issue: 03/19/2021

stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 06/20/2025

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8